ceftriaxone + metronidazole + rifampicin + moxifloxacin

This is a combination of four antibiotics: **ceftriaxone** (a third-generation cephalosporin), **metronidazole** (a nitroimidazole antibiotic), **rifampicin** (a rifamycin antibiotic), and **moxifloxacin** (a fluoroquinolone antibiotic). These drugs act via different mechanisms to provide broad-spectrum coverage against a wide array of bacteria, including Gram-negative, Gram-positive, anaerobic organisms, and atypical pathogens. This multi-drug regimen may be used in complex or refractory polymicrobial infections where broad and synergistic antimicrobial activity is required. Ceftriaxone inhibits bacterial cell wall synthesis, metronidazole disrupts DNA and inhibits nucleic acid synthesis in anaerobes and protozoa, rifampicin blocks bacterial RNA synthesis by inhibiting DNA-dependent RNA polymerase, and moxifloxacin inhibits the bacterial DNA gyrase and topoisomerase IV, interrupting DNA replication and repair. This specific four-drug combination has been studied, among other contexts, for the targeted treatment of severe cases of **hidradenitis suppurativa**, as well as theoretically in polymicrobial or multi-resistant intra-abdominal or skin/soft tissue infections[4][7].